We then selected a panel of molecules with pan (AR-42, belinostat) or selective (entinostat, class 1/2) HDAC inhibitory activity based on their potential in clinical translation in high-risk-AML. The gene discussed is HDAC9; the disease is acute myeloid leukemia.